NCT00268996 - Integrated Biomarker And Imaging Study - 2 | Biotech Hunter

Enrollment

336

Participants

Timeline

Start Date

November 10, 2005

Primary Completion Date

August 28, 2007

Study Completion Date

August 28, 2007

Conditions

Atherosclerosis

Interventions

DRUG

SB-480848

SB-480848 is available as enteric-coated, free-base micronized tablet

DRUG

SB-480848 matching placebo

Placebo is available as enteric-coated, free-base micronized tablet

Trial Locations (26)

2020

GSK Investigational Site, Antwerp

4000

GSK Investigational Site, Liège

5053

GSK Investigational Site, Bergen

6000

GSK Investigational Site, Lucerne

9300

GSK Investigational Site, Aalst

22527

GSK Investigational Site, Hamburg

23795

GSK Investigational Site, Bad Segeberg

25000

GSK Investigational Site, Besançon

28040

GSK Investigational Site, Marid

29609

GSK Investigational Site, Brest

38008

GSK Investigational Site, Santander

45122

GSK Investigational Site, Essen

61231

GSK Investigational Site, Bad Nauheim

69120

GSK Investigational Site, Heidelberg

80336

GSK Investigational Site, Munich

89081

GSK Investigational Site, Ulm

A-1140

GSK Investigational Site, Vienna

128 08

GSK Investigational Site, Prague

DK-8200

GSK Investigational Site, Aarhus N

5623 EJ

GSK Investigational Site, Eindhoven

7511JX

GSK Investigational Site, Enschede

8934 AD

GSK Investigational Site, Leeuwarden

3015 GD

GSK Investigational Site, Rotterdam

3075 EA

GSK Investigational Site, Rotterdam

40-635

GSK Investigational Site, Katowice

31-501

GSK Investigational Site, Krakow